BioSpace News Archive

A trustee with the DOJ filed a request for an “expedited stay” in order to prevent the initiation of the bankruptcy plan.

Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.

With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

From time to time, the U.S. FDA requests additional data from companies who have submitted an application for a new drug or biologic. What’s a bit unusual is every single PDUFA date this week had that happen.

The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.

COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.

Vifor Pharma Group and Travere Therapeutics inked a collaborationfor the commercialization of sparsentan for the treatment rare progressive kidney diseases.

In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend the FDA grant Emergency Use Authorization for a booster dose of COMIRNATY® in individuals 65 years of age and older and individuals at high risk of severe COVID-19.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement restricted stock units.